Showing results (1-10 of 66) with videos related to
Sort By:
Pageof 7
Metabolites|November 25, 2021
Cardiovascular Safety of Anti-Sclerostin Therapy in Chronic Kidney DiseaseDaniel CejkaCurrent Opinion in Nephrology and Hypertension|April 16, 2019
An overview of the mechanisms in vascular calcification during chronic kidney diseaseJakob Voelkl, Daniel Cejka, Ioana AlesutanClinical Science (London, England : 1979)|December 13, 2005
Short interfering RNA (siRNA): tool or therapeutic?Daniel Cejka, Doris Losert, Volker WacheckKidney & Blood Pressure Research|July 1, 2010
Treatment of Hemodialysis-Associated Adynamic Bone Disease with Teriparatide (PTH1-34): A Pilot StudyDaniel Cejka, Katharina Kodras, Till Bader, et al.Frontiers in Medicine|July 5, 2021
Propensity for Calcification in Serum Associates With 2-Year Cardiovascular Mortality in Ischemic Heart Failure With Reduced Ejection FractionMarija Bojic, Lorenz Koller, Daniel Cejka, et al.The Journal of Clinical Endocrinology and Metabolism|September 13, 2014
Low-dose calcium versus pentagastrin for stimulation of calcitonin in chronic hemodialysis patients: a pilot studyUrsula Thiem, Rodrig Marculescu, Daniel Cejka, et al.Thrombosis and Haemostasis|October 31, 2021
Calcification Propensity in Serum and Cardiovascular Outcome in Peripheral Artery DiseaseMarija Bojic, Bernhard Bielesz, Daniel Cejka, et al.Wiener Klinische Wochenschrift|October 17, 2022
Value of SGLT-2 inhibitors in the treatment of chronic kidney disease : Clinical and practical implicationsMarcus Säemann, Daniel Cejka, Sabine Schmaldienst, et al.Atherosclerosis|March 10, 2023
Secondary calciprotein particle size is associated with patient mortality in peripheral artery diseaseMarija Bojic, Daniel Cejka, Bernhard Bielesz, et al.Pageof 7